It is important to remember that as for any medical treatment, improvements cannot be guaranteed. Please contact us for more information regarding the possible improvements for a particular case.
Stem Cell Quality and Quantity Ensured
Different types of stem cells for different needs
Beike provides stem cells from two separate sources: umbilical cord blood and umbilical cord tissue. Umbilical cord related samples are donated by healthy mothers after normal births and are sent to Beike Biotech's laboratories for processing.
After reviewing the patient’s full medical information, our doctors will recommend which source of stem cells should be used for treatment. Our treatment protocols may include one or multiple types of stem cell in combination depending on each patient's specific condition.
Highest International Stem Cell Processing Standards
Beike Biotechnology is processing its own adult stem cells in its internationally accredited laboratories. The company has full control over the processing and quality control of all stem cell products, ensuring perfect safety and highest quality. Processing methods and facility are accredited by the American Association of Blood Banks (AABB), the highest international standard in the industry.
Below are video interviews recorded during treatment with Beike stem cells. The families showcased in these videos talk about their personal stories and their experience of the treatment including the improvement noticed. The improvements mentioned in these videos are typical, however it does not guarantee that all patients may have the same improvements.
Extensiveness: A complete supportive therapy program is provided daily to stimulate patient's freshly transplanted stem cells. The best improvement can only be obtain by supporting your stem cells.
Support: A full follow-up program is provided after the treatment and you will be asked to take part in it at 1, 3, 6 and 12 months after treatment. Access to our team after the treatment is very important as you may receive further advice to maximize improvements.
Learn More About Us
Founded in July 2005, Shenzhen Beike Biotechnology Co. Ltd. (hereinafter referred to as Beike Biotechnology) is a national high-tech enterprise specialized in clinical transformation and technical service of biological treatment technology of strategic emerging industries.
Get more information now
More About ONH-SOD
What is optic nerve hypoplasia (ONH) and septo-optic dysplasia (SOD)?
Optic nerve hypoplasia (ONH) occurs from the underdevelopment of the optic nerve, which carries neuronal transmission from the retina in the eye to the brain1. It is the leading cause of congenital blindness and occurs in approximately 10 in every 100,000 live births. The condition was first described in 1915.
Septo-optic dysplasia (SOD) – also known as de Morsier syndrome – is a subtype of ONH and results from underdevelopment of the optic nerve, pituitary gland dysfunction, and absence of the septum pellucidum, which is a midline area of the brain. SOD arises from defects during the embryological development of infants.
What causes ONH and SOD?
There are numerous causes of ONH, with most cases arising from genetic abnormalities in patients. Mutations in a variety of genes, including the following, result in hypoplasia of the optic nerve: NR2F1, OTX2, VAX1, ATOH7.
In addition to genetic factors, other causative factors have been suggested, including exposure to various infections during pregnancy and endocrinological abnormalities during development.
With respect to SOD, as previously eluded to earlier, the condition arises from abnormalities during embryological development. The exact cause of SOD is poorly understood; although it is likely genetic factors play an important role, with various patients exhibiting mutations in the genes HESX1, OTX2, and PAX6. In addition, exposure to certain medications, such as sodium valproate during pregnancy, is thought to play an important role in the development of SOD.
How are ONH and SOD diagnosed?
Diagnosis of ONH requires confirmation with ophthalmoscopic examination of the optic optic disc. In young children, the optimal method for diagnosing ONH is with direct ophthalmoscopy, and patients exhibit a small optic disc. SOD is differentiated by the use of MRI scans showing midline brain abnormalities such as corpus callosum hypoplasia or pituitary abnormalities1.
What are the current treatments for ONH and SOD?
Currently, no treatments exist that can cure or reverse the symptoms exhibited by patients with ONH and SOD. The treatment for ONH is directed toward the specific symptoms exhibited by each individual. Treatment often necessitates coordinated efforts of a team of specialists including pediatricians, ophthalmologists, neurologists, endocrinologists and other health care professionals. Hormone deficiencies are treated with hormone replacement therapy, often directed by endocrinologists. However, vision abnormalities are usually not treatable in both ONH and SOD patients, although patients may seek help from low vision specialists.